Coats Group plc earnings date
Coats Group plc (4TC) Q2 2026 Earnings Report
DE:4TC Q2 2026 EPS Results
- Actual EPS
- EUR 0.04
- Consensus EPS
- EUR 0.04
- Beat/Miss
- Missed by -EUR 0.00
- One Year Ago EPS
- EUR 0.04
DE:4TC Q2 2026 Revenue Results
- Actual Revenue
- EUR 724.01M
- Expected Revenue
- EUR 730.55M
- Beat/Miss
- Missed by -EUR 6.54M
- YoY Revenue Growth
- +14.37%
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 07/28/2026
- Time
- Before Open
- Conference Call
- Tuesday, July 28, 2026
Coats Group plc's next earnings date is estimated for March 11, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
The call conveyed a broadly positive operational and strategic performance despite a challenging macro backdrop. Key strengths included market outperformance (1% organic growth against mid-single-digit market declines), maintained near-20% group EBIT margin, identified significant OrthoLite synergies (both cost and material incremental sales synergies), strong cash generation (H1 free cash flow $30m) and increased dividend. Challenges were mainly acquisition-related (OrthoLite short-term revenue softness from capacity constraints), higher interest costs and a modest decline in EPS and some divisional margin pressure driven by strategic investments. Management reiterated unchanged guidance, confidence in H2 improvement and a clear plan to deliver additional cost benefits and revenue synergies.
Guidance for 2026 was maintained: management expects an H2 improvement in EBIT despite assuming modest end‑market declines, driven by secured pricing, supply stability and around $15m of incremental cost benefits in H2 (including $5m of OrthoLite synergies), with profit "in line with market expectations" and good year‑on‑year earnings growth; working capital is expected to significantly unwind in H2 with working capital running at ~12% of sales for the full year; FY capex remains $40–45m plus $5m for a Coats capacity expansion (production from Q1 2027); OrthoLite synergies remain on track ($5m in 2026, at least $20m by 2028) and $40m+ of incremental annual sales synergies identified by 2030; the group sits with net debt of $842m (pro‑forma leverage 2.3x at H1) and remains fully on track to reduce leverage to ≤2x by year‑end, while delivering strong free cash flow (H1 pre‑dividends $30m) and targeting $1bn cumulative free cash flow over the next five years.
- Organic Revenue Growth and Market OutperformanceGroup revenue of $837 million, up 1% on an organic constant exchange rate basis, achieved while apparel and footwear end markets declined by mid-single digits — demonstrating consistent outperformance versus end markets.
- Strong Group Margin MaintainedEBIT of $166 million with an EBIT margin maintained at 19.8% (just below 20%), including a 40-basis-point margin accretion benefit from the OrthoLite acquisition.
- Apparel Division Share Gains and GrowthApparel revenue $486 million, up 1% on an organic CER basis, with significant market share gains across the portfolio, strong growth in China domestic market and automotive threads, and leadership in 100% recycled thread products.
- Footwear Momentum and OrthoLite Strategic ValueFootwear revenue $351 million (flat organic), with clear Q2 acceleration (6% organic growth in Q2) and gains in footwear thread and structural components. OrthoLite acquisition has increased strategic scale and capability and contributed margin accretion to the division.
- OrthoLite Synergies and UpsideOn track to deliver announced cost synergies (including $5 million in the current year and at least $20 million by 2028) and identified $40 million of additional annual sales synergies not included in the original acquisition case; OrthoLite core addressable market forecasted to grow from $700 million (2024) to ~$1 billion by 2030.
- Cash Generation and Balance Sheet ProgressFree cash flow pre-dividends of $30 million in H1; net debt $842 million (pro forma leverage 2.3x) with management on track to reduce leverage to 2.0x or below by year-end; successful refinancing of bridge and term facilities.
- Dividend Increase and Capital DisciplineInterim dividend of $1.05, up 5% versus H1 2025; capital expenditure disciplined at $16 million in H1 with FY 2026 guidance maintained at $40–45 million plus $5 million for authorized capacity expansion.
- Progress in Adjacent Growth Areas and DigitalTarget adjacencies contributed c.1% of group revenue growth in H1. Notable examples include composite energy tapes (growth from $11m in 2025 to >$40m targeted by 2030) and Coats Digital showing bookings growth of 57% in H1 following new AI-enabled product rollout.
- H2 Confidence and Cost ActionsManagement expects an EBIT improvement in H2 assuming modest end-market declines, with incremental cost actions and OrthoLite synergies expected to deliver about $15 million of benefit in H2 and working capital unwind supporting cash generation.
DE:4TC Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 11, 2027 | 2026 (Q4) | 0.05- | 0.04 | ― | ― |
| Jul 28, 2026 | 2026 (Q2) | 0.040.04 | 0.04 | -4.35% (-0.00) | |
| Mar 05, 2026 | 2025 (Q4) | 0.040.04 | 0.04 | -8.51% (-0.00) | |
| Jul 16, 2025 | 2025 (Q2) | 0.040.04 | 0.04 | 4.55% (+0.00) | |
| Mar 06, 2025 | 2024 (Q4) | 0.040.04 | 0.04 | 4.44% (+0.00) | |
| Aug 01, 2024 | 2024 (Q2) | 0.040.04 | 0.03 | 25.71% (+0.01) | |
| Mar 07, 2024 | 2023 (Q4) | 0.040.04 | 0.03 | 28.57% (+0.01) | |
| Aug 01, 2023 | 2023 (Q2) | 0.030.03 | 0.04 | -18.60% (-0.01) | |
| Mar 02, 2023 | 2022 (Q4) | 0.030.03 | 0.03 | -7.89% (-0.00) | |
| Aug 02, 2022 | 2022 (Q2) | 0.040.04 | 0.03 | 38.71% (+0.01) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

